Two patients taking cabergoline had improvements in their Parkinson's disease symptoms while taking itraconazole. In one case a 300% increase in cabergoline levels occurred, and the other patient reduced the dose of her medications without adversely affecting disease control. It would be prudent to monitor toxicity and efficacy in any patient taking cabergoline with itraconazole, or similar potent inhibitors of CYP3A4 such as ketoconazole.
(21)
This site is intended for general information only. The information provided on this site does not constitute medical advice and should not be relied upon. You should not act or refrain from acting on any legal or medical matter based on the content of this site.